SCHEMBL19968846

SCHEMBL19968846

CC1(O)CN(c2cccc(S(=O)(=O)Nc3ccc(Cl)c(-c4ccc(F)cc4Cl)n3)n2)C1

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KIF18A Q8NI77 5/20 0.36
GHSR Q92847 1/20 0.34
SLC22A12 Q96S37 1/20 0.33
SCN9A Q15858 2/20 0.32
SCN5A Q14524 2/20 0.32
CTSS P25774 1/20 0.32
PTPN11 Q06124 1/20 0.32
KMO O15229 2/20 0.31
SCN10A Q9Y5Y9 1/20 0.31
BRD4 O60885 1/20 0.31
ABL1 P00519 1/20 0.31
PKLR P30613 1/20 0.31
SCN1A P35498 2/20 0.30
SCN8A Q9UQD0 2/20 0.30
IGF1R P08069 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19927752 0.86 PTPN11 (0.36) KIF18AGHSRSLC22A12PTPN11PKLR
SCHEMBL19928383 0.86 GHSR (0.38) GHSRSLC22A12SCN9ASCN5ACTSS
SCHEMBL19925071 0.84 HTR3E (0.39) GHSRSLC22A12SCN9ACTSSPTPN11
SCHEMBL19925027 0.83 KIF18A (0.38) KIF18A
SCHEMBL19925200 0.82 LMNA (0.35) KIF18ASCN9AABL1
SCHEMBL19928774 0.82 ABL1 (0.34) GHSRSLC22A12SCN5AKMOABL1
SCHEMBL19925199 0.81 KIF18A (0.36) KIF18AGHSRSCN9AKMOSCN1A
SCHEMBL19951446 0.81 HSD11B1 (0.35) KIF18AABL1
SCHEMBL19925028 0.80 SOS1 (0.36) KIF18ASLC22A12
SCHEMBL19968848 0.80 KIF18A (0.37) KIF18ASCN9APTPN11ABL1SCN1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641873-B N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease 诺华股份有限公司 2022-03-18 CN claimed
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP claimed
CN-109641873-B N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease 诺华股份有限公司 2022-03-18 CN disclosed
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2021-07-20 US disclosed
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066369-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 KIF18A 4084/4885GHSR 2080/4885SLC22A12 594/4885
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 KIF18A 4084/4885GHSR 2080/4885SLC22A12 594/4885
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 KIF18A 4084/4885GHSR 2080/4885SLC22A12 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.